The UK-based venture capital company 4BIO Capital has promoted two of its officers as it steps up its presence in the fields of cell and gene therapy, RNA-based medicines, and the microbiome. Owen Smith has become a partner and Vasily Fedorin has been named chief operating officer. Mr Smith joined 4BIO in 2018 and is currently a director of the portfolio companies Locki Therapeutics Ltd, an oncology company, and SparingVision SAS, an ocular medicine concern. He holds a master of science degree in experimental and translational therapeutics from the University of Oxford and is also qualified as an accountant.
Mr Fedorin joined 4BIO in 2015. He previously worked at the International Foundation of Technology and Investment, a not-for-profit science organisation in Russia. He holds a PhD in neuroscience from the Lomonosov Moscow State University.
4BIO Capital announced the appointments on 2 March 2022.
Copyright 2022 Evernow Publishing Ltd